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In Japan, a research center network consisting of Kyoto University to provide clinical-grade induced
Pluripotent Stem Cells (iPSC) and several major research centers to develop iPSC-based regenerative
therapies was formed for the clinical application of iPSCs. This network is under the supervision of a
newly formed funding agency, the Japan Agency for Medical Research and Development. In parallel,
regulatory authorities of Japan, including the Ministry of Health, Labour and Welfare, and Pharmaceu-
ticals and Medical Devices Agency, are trying to accelerate the development process of regenerative
medicine products (RMPs) by several initiatives: 1) introduction of a conditional and time-limited
approval scheme only applicable to RMPs under the revised Pharmaceuticals and Medical Devices Act,
2) expansion of a consultation program at the early stage of development, 3) establishment of guidelines
to support efﬁcient development and review and 4) enhancement of post-market safety measures such
as introduction of patient registries and setting user requirements with cooperation from relevant ac-
ademic societies and experts. Ultimately, the establishment of a global network among iPSC banks that
derives clinical-grade iPSCs from human leukocyte antigens homozygous donors has been proposed. In
order to share clinical-grade iPSCs globally and to facilitate global development of iPSC-based RMPs, it
will be necessary to promote regulatory harmonization and to establish common standards related to
iPSCs and differentiated cells based on scientiﬁc evidence.
© 2016, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Introduction
Induced pluripotent stem cells (iPSCs) were ﬁrstly made from
mice in 2006 [1] and from humans in 2007 [2,3]. iPSCs share many
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tools for drug toxicity testing, such as drug-induced QT prolonga-
tion [4e6]. A unique application of iPSCs is that they can be derived
from diseased patients, which gives them a distinct advantage over
ESCs for disease modeling and drug discovery [7e21].
Regarding cell therapy applications, it is expected that iPSC-
based products from healthy donors can be used for allogeneic
therapies. By carefully selecting donors that have homozygous
human leukocyte antigens (HLA), it will be possible to reduce im-
mune rejection and thus also the dose of immunosuppressive
agents [22e35]. In addition, iPSCs have the potential for autologous
therapies, further reducing the risk of immune rejection [36,37].
In Japan, the discovery of iPSCs has stimulated strong govern-
ment support for the development and commercialization of iPSC-
based technology, including generous research funding. This sup-
port was ampliﬁed after the Nobel Prize in Physiology or Medicine
was awarded in 2012. In addition, regulatory authorities have
reevaluated policy in order to facilitate effective and efﬁcient reg-
ulatory clearance for marketing approval of this technology
[38e45]. In this manuscript, we will review relevant policies and
collaborative efforts among academia, industry and government
agencies. We also discuss potential regulatory and ethical chal-
lenges related to future international cooperation for HLA homo-
zygous iPSC banks, which are being used as sources for iPSC-based
regenerative medicine products (RMPs).
2. Role of public funding to facilitate R&D on iPSC-based
regenerative therapies
2.1. Establishment of Japan Agency for Medical Research and
Development
In order to promote medical research and development (R&D),
including regenerative medicine, the Japan Agency for Medical
Research and Development (AMED) was established as a new Na-
tional Research and Development Agency on April 2015 [40,43,46].
AMED is organized to consolidate national medical R&D funding,
which was previously operated directly by the Ministry of Educa-
tion, Culture, Sports, Science and Technology (MEXT), Ministry of
Health, Labour and Welfare (MHLW) and Ministry of Economy,
Trade and Industry (METI) or through the Japan Science and
Technology Agency (JST), National Institute of Biomedical Innova-
tion (NIBIO) and New Energy and Industrial Technology Develop-
ment Organization (NEDO) [47]. AMED also consolidates the
operation of the research center network for realization of regen-
erative medicine (ﬁscal year (FY) 2015 budget: 8.99 billion yen)
from MEXT, regenerative medicine clinical application program
(FY2015 budget: 2.78 billion yen) from MHLW and regenerative
medicine industrial technology development support program
(FY2015 budget: 2.5 billion yen) from METI (Fig. 1) [48,49].
2.2. Collaboration for regenerative medicine related to the iPSC
stock project
For R&D toward iPSC-based regenerative therapies, close
collaboration between research centers that generate and provide
(or distribute) iPSCs and those that differentiate iPSCs into ﬁnal
products are important. Therefore, MEXT and JST initiated a new
program, “Research center network for realization of regenerative
medicine” in FY 2013 (Fig. 2) [50]. Under this program, the Center
for iPS Cell Research and Application (CiRA), Kyoto University, was
selected as a core center for iPSC research to conduct “iPSC stock
development projects for regenerative medicine”. Four research
centers (Keio University, CiRA, Riken and Osaka University) were
selected as “Centers for Clinical Application Research on SpeciﬁcDisease/Organ (Type A Centers/Institutions)”, which aim at the
clinical application of iPSC-based regenerative therapies by FY 2017,
making them national leaders in iPSC-based regenerative therapy
R&D. Overall, the program consists of many other iPSC-based
regenerative therapy R&D projects. Table 1 shows examples of
disease/organ research projects related to iPSC-based regenerative
therapy being done by at least one of the four institutions under
this program. Many of these projects involve collaborations using
the iPSC stocks provided by CiRA.
One of the primary roles of CiRA is to provide seed stocks of
iPSCs for the development of therapeutic products [51e53]. The
stock generated from HLA-homozygous donors is expected to
reduce the risk of immune rejection upon the transplantation of
differentiated cells to recipients having the same HLA haplotype
[22e35]. Therefore, CiRA is developing a series of clinical grade
iPSCs from HLA-homozygous donors in collaboration with the
Japan Red Cross, the Japan Marrow Donor Program and cord blood
banks.
In general, user research centers will expand and establish their
own cell banks of iPSCs or of downstream stem/progenitor cells for
pre-clinical and clinical studies. In the case that the research center
derives iPSCs from a source other than the CiRA iPSC stock for
therapeutic purposes, CiRA will provide technical assistance when
necessary. For example, the two institutes will characterize and
analyze the iPSC-based differentiated cells together. For the
development of iPSC-based regenerative therapy, in addition to
general pre-clinical toxicity testing, additional consideration of
tumorigenicity related to residual undifferentiated cells, contami-
nant cells, cells genetically transformed to malignancy during cul-
ture, or residual vectors is essential [54e63]. The relationship
between genomic abnormalities of iPSCs or ﬁnal products and
tumorigenicity is not yet elucidated. To appropriately analyze
genomic abnormalities of the ﬁnal products, it is necessary to
compare genome information from the original donor cells, iPSCs
and differentiated cells. CiRA will be responsible for the genome
analysis, and user research centers will be responsible for tumori-
genicity studies. The results of these works will be used to optimize
quality standards for both iPSCs as raw material and differentiated
cells as ﬁnal products.2.3. Expansion of clinical research infrastructure
To facilitate academia-based clinical research of iPSC-based
regenerative therapies, collaboration with hospitals that have ex-
perts who can prepare clinical research protocols and manage
clinical research, is important. Therefore, MHLW and MEXT started
several grants for clinical research infrastructure [40]. These grants
facilitate early-phase and exploratory clinical trials using iPSC-
based regenerative therapies. Osaka University and Keio Univer-
sity Hospitals have been awarded the early/exploratory clinical trial
center grant since 2011 [64], and Kyoto University Hospital the
clinical research core center grant since 2012 [65]. MHLW certiﬁed
Institutional Review Boards (IRBs) at these three institutions in
April 2015 based on a new certiﬁcation program [66]. Osaka, Keio
and Kyoto Universities also established specially certiﬁed regener-
ative medicine committees to review clinical research protocols for
iPSC-based therapies under the new Act on the Safety of Regener-
ative Medicine (RM Act) enacted in November 2014 [39,43,67,68].
Although the Center for Developmental Biology (CDB), Riken, does
not have its own hospital, it has already begun iPSC-based retinal
pigment epithelium (RPE) clinical research by coordinating with
Institution of Biomedical Research and Innovation (IBRI) Hospital,
which has been awarded the Japan initiated global trial center grant
since 2012 [69]. These grants were transferred from MHLW to
MEXT-AMED 
research center 
network for 
realization of 
regenerative 
medicine
MHLW-AMED 
regenerative 
medicine clinical 
application 
program
company-
sponsored 
clinical trial
Conditional 
and time-
limited
marketing 
approval
Pharmaceutical affairs consultation 
on R&D strategy with user fee 
discount for academia and start-ups
Human resource exchange between PMDA-
academia and draft guidance development
Protocol development and support for clinical research 
by AMED grant program (clinical research core 
hospital etc.)
User requirement development 
for appropriate post-market use
Introduction of post-
market patient registry
Post-market 
follow-up
and regular 
marketing
approval
Support programs by 
regulator for 
innovative 
regenerative medicine 
products
(MHLW & PMDA)
Funds for individual R&D projects
(AMED regenerative medicine realization highway framework)
Clinical research 
infrastructure 
development (AMED)
METI-AMED regenerative medicine industrial 
technology development support program
Basic 
research
Pre-clinical 
study Clinical study Commercialization
Drug Master File registration and review of raw 
materials under trade secret protection
Fig. 1. Overview of support programs for the R&D of regenerative medicine products. AMED, Japan Agency for Medical Research and Development; MEXT, Ministry of Education,
Culture, Sports, Science and Technology; MHLW, Ministry of Health, Labour and Welfare; METI, Ministry of Economy, Trade and Industry.
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eration center program” [48,49].2.4. Collaboration between PMDA and research institutions to
develop guidelines for iPSC-based regenerative medicine products
A unique scheme that encourages close interactions between
regulatory authorities and research institutions was introduced
recently in Japan. For innovative products under development by
academia, such as iPSC-based RMPs, regulatory requirements have
sometimes been unclear. However, effective regulatory guidelines
cannot be made by the regulatory authorities without input from
active scientists. Therefore, MHLW initiated a new grant program,
“Initiative for Accelerating Regulatory Science in Innovative Drugs,
Medical Devices and Regenerative Medicine”, in 2012 [70,71]. R&D
programs related to iPSC-based RMPs at CiRA, Osaka University and
Riken CDB have been awarded these grants. In this program, re-
viewers at the Pharmaceuticals and Medical Devices Agency
(PMDA) or scientiﬁc experts at National Institute of Health Science
(NIHS) visit research institutions periodically to give scientiﬁc
advise and remain updated with on-going development of inno-
vative technologies. In exchange, researchers visit PMDA as part-
time or full-time employees and provide technical advice to sup-
port PMDA's review and consultation. The intent of these bi-
directional exchanges is to have all parties better understand
their partners' motivations and goals. An expected outcome of this
ﬁve-year program (FY2012eFY2016) is to have researchers and
PMDA's or NIHS's visiting scientists together develop a draft of
guidelines. After appropriate public consultation, MHLW will
ﬁnalize and publish these documents as ofﬁcial guidelines thatclarify regulatory requirements to facilitate the commercialization
of innovative iPSC derived RMPs.
In addition to this scheme, there are other mechanisms for
developing such guidelines. One is MHLW's regulatory science
research grants, which have led to general guidelines for iPSC-
based RMPs that were published in 2012 [72e75]. Another is a
speciﬁc program that began in 2006 and drafts evaluation guidance
for innovative products. Under this program, MHLW, NIHS, and
PMDA work together with academic experts and have published
guidelines for iPSC-based RPE cells in 2013 (autologous) and 2014
(allogeneic) [76,77]. Currently, new guidelines for iPSC-based
cartilage products are under preparation [78].
3. Revised regulatory policy to promote R&D of RMPs
Along with the actions described above, there are several
regulator-led initiatives that are designed to promote the R&D of
RMPs (Fig. 1). In this section, we review current regulatory policy
related to RMPs relevant to future iPSC-based RMPs.
3.1. Introduction of conditional, time-limited approval for RMPs
The Pharmaceutical Affairs Law (PAL) was revised and renamed
to the Pharmaceuticals and Medical Devices (PMD) Act, which
became effective in November 2014 [38e45,79,80]. In this revision,
a new product category, RMPs, which is separate from drugs and
medical devices, was introduced, and its speciﬁc regulation was
established. Because RMPs are extremely difﬁcult to evaluate for
effectiveness due to the heterogeneity of cells, a new approval
system in which MHLW can give conditional and time-limited
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Fig. 2. iPSC stock related R&D collaboration involving major research centers and regulatory agencies. AMED, Japan Agency for Medical Research and Development; MHLW,
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Table 1
iPSC-based regenerative therapy R&D projects under the AMED regenerative medicine network program.
Kyoto University Riken Osaka University Keio University
Dopamine-producing neurons Retinal pigment epithelium cells Corneal epithelium cells Neural progenitor cells
Platelet Photoreceptor cells Corneal endothelium cells Corneal endothelium cells
Cartilage Natural killer T cells Cardiomyocytes Cardiomyocytes
Cardiomyocytes Teeth Hepatocytes
Kidney Hair
Pancreas Secretory glands
Skeletal muscle
Note: Other institutions participating but not shown include Osaka National Hospital (neural progenitor cells), Yokohama City University (liver), the University of Tokyo (liver
and pancreas), Kumamoto University (liver), Chiba University (liver) and National Center of Neurology and Psychiatry (skeletal muscle).
Reference: summarized from the JST regenerative medicine network program website (http://www.jst.go.jp/saisei-nw/).
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introduced. Upon this probationary approval, approval holders
must apply for regular approval within a speciﬁed period (normally
maximum 7 years) or the approval will expire. In addition, Good
Manufacturing Practice (GMP) that considers the unique charac-
teristics of RMPs was introduced as Good Gene, Cell, Cellular and
Tissue-based products Manufacturing Practice (GCTP) [81].
Under the new PMD Act, two products were approved as new
RMPs on September 18 2015. One product, Temcell® HS Inj. by JCR
Pharmaceuticals Co., Ltd for Acute Graft-versus-Host Disease
following hematopoietic stem cell transplant, was awarded regular
approval [82,83]. Another product, HeartSheet® Autologous Skel-
etal Myoblast Sheets by Terumo Corporation for severe heart failurecaused by chronic ischemic heart disease, was awarded conditional
and time-limited approval for 5 years [84,85].
3.2. Introduction of new consultation program for early stage
development and simpliﬁcation of clinical trial plan review
Under the PMD Act, article 80-2, intensive review by PMDA and
MHLW is required for the ﬁrst clinical trial protocol of any new
drug, medical device or RMP within 30 days of application sub-
mission. However, this time period is demanding when considering
the quality and safety of RMPs. Therefore, pre-clinical review by the
Pharmaceutical and Medical Device Evaluation Center of NIHS
(consolidated to the PMDA in 2004) and the MHLW Pharmaceutical
K. Azuma, S. Yamanaka / Regenerative Therapy 4 (2016) 36e4740and Food Sanitation Council before submission of the ﬁrst clinical
trial protocol had been required since 1999 [86e88].
Prior to the recent revision of the PMD Act, MHLW held “the
committee of regenerative medicine regulatory framework”, which
consisted of regenerative medicine experts, from 2009 to 2011. This
committee discussed improvements to the PMDAct. Accordingly, in
July 2011, MHLW and PMDA introduced an early stage consultation
program that mainly targets academia and start-up companies and
replace the ofﬁcial additional pre-clinical review of quality and
safety of RMPs [89,90]. In this new consultation program, named
pharmaceutical affairs strategy consultation, PMDA gives advice
related to R&D strategy [91]. The review of quality and safety data
under the pharmaceutical affairs strategy consultation is required
before submission of the ﬁrst clinical trial protocol for any RMP.
Pharmaceutical affairs strategy consultation usually requires fees
for each ofﬁcial meeting, but for the mandatory consultation
related to quality and safety, a one-time consultation fee can be
paid. In addition, by subsidy from MHLW, discounts of up to 90%
can be procured for academia and start-up companies. This
consultation has considerably simpliﬁed pre-clinical reviews and
reduced uncertainty of what quality and safety data are required in
the pre-clinical phases because of constant communication be-
tween the sponsors and PMDA. CiRA has used this pharmaceutical
affairs strategy consultation to conﬁrm the quality and safety of its
iPSC stocks and other iPSC-based RMPs [92].
More recently, MHLW announced the introduction of fast-track
consultation and review program designed speciﬁcally for drugs,
medical devices and RMPs that act against diseases in urgent need
of innovative therapy and are initially developed in Japan or will
include Japan in a multi-national clinical trial [93,94].
3.3. Expansion of Drug Master File registration systems for raw
materials of RMPs
A Drug Master File (DMF) registration system for the raw ma-
terials of drugs or medical devices, such as active pharmaceutical
ingredients, was introduced in 2005 [95]. This system allows PMDA
to review information directly submitted by raw material manu-
facturers who are not applying for clinical trials or seeking regu-
latory approval, thus allowing these manufacturers to protect trade
secrets. In December 2012, subjects of DMF registration were
expanded to include raw materials related to RMPs, such as cells
(iPSCs and ESCs), media, medium additives (sera, growth factors
and cytokines) and other materials [96,97]. Raw material manu-
facturers can directly register manufacturing and quality control
information, speciﬁcations related to human or animal derived
materials, information related to the donors of the cells, speciﬁca-
tions of the cells and non-clinical test data [98,99]. These data can
be reviewed directly by PMDA not only during the approval review,
but also before clinical trials, including during the pharmaceutical
affairs strategy consultation, to conﬁrm the quality and safety of the
raw materials and ﬁnal products.
3.4. Introduction of post-market patient registry for RMPs
Unlike most drugs, which disappear within a few days by
metabolism or elimination after the end of administration, many
RMPs stay in the patient body long after transplantation. Therefore,
long-term patient follow-up is essential for reliable evaluation.
From this perspective, RMPs share similar characteristics with
implantable medical devices, such as left ventricular assist devices
or hip replacement implants, which are often included in a patient
registry for recognition of post-market safety issues [100,101].
PMDA has experience in developing and operating J-MACS (Japa-
nese registry for Mechanically Assisted Circulatory Support), whichis a patient registry for mechanical circulatory support implanta-
tion devices and built on a similar data structure as North America's
INTERMACS (Interagency Registry for Mechanically Assisted Cir-
culatory Support) [102e106]. Leveraging this experience and in
response to the introduction of the new conditional, time-limited
approval system, a new patient cohort registry that records post-
market safety and efﬁcacy data of RMPs is currently under devel-
opment by MHLW and PMDA [41,44].
A MHLW-sponsored committee to discuss the design of a pa-
tient registry system for RMPs was formed in January 2013. Based
on their conclusions, PMDA commenced the development of a
registry, aiming for launch by the end of FY2015 [107,108]. It is
expected that this new patient cohort registry of RMPs will
generate useful post-market safety and efﬁcacy data, which can be
used for regular approval review after conditional and time-limited
approval.
3.5. User requirements for appropriate use of RMPs
Another safety measure to consider for conditional, time-
limited approval is the requirements of users, such as medical
institutions and medical doctors, for RMPs that require novel or
complex surgical techniques. In 2011, in response to increasing
complexity, MHLW introduced a new program to facilitate the
development of post-market user requirements for facilities and
physicians [109]. In this program, MHLW, PMDA and related
academic societies worked together to set post-market user re-
quirements during the approval review of innovative medical
devices and RMPs. These requirements have been adopted as
conditions for National Health Insurance reimbursement
coverage. These standards are already being applied to an
autologous cultured cartilage product, JACC®, that is manufac-
tured by Japan Tissue Engineering Co., Ltd. and was approved in
July 2012 [110e114]. The Japanese Orthopaedic Association
proposed the user requirements of JACC®, including the neces-
sary facilities, human resources, experience, training, expertise,
etc. [115]. These standards are also used to determine the con-
ditions for reimbursement [116,117]. Currently, user re-
quirements for autologous skeletal muscle derived cell sheets for
heart failure are under preparation [118]. It is expected that
future iPSC-based RMPs will also fall under this scheme and
appropriate human and facility standards in order to secure the
product efﬁcacy and safety set by MHLW, PMDA and relevant
professional societies.
3.6. Alternative scheme to provide regenerative therapies under
early stage, small-scale human clinical research
Apart from clinical trials under the PMD Act, which aims for the
commercialization of RMPs, there is an alternative scheme to use
iPSC-based regenerative therapies under physician discretion. This
scheme is recognized as “clinical research” and is not intended for
commercialization [40,43,86,87]. It is unique to Japan, but shares
some common characteristics with the “Hospital Exemption”
scheme in EU member states [119].
Until recently, clinical research using human stem cells was
regulated under the independent, non-legally binding guideline,
“Guidelines for Clinical Research Using Human Stem Cells” [120].
The RM Act [41,43,68], enacted since November 2014, replaced this
guideline. The RM Act stipulates stricter standards to provide
regenerative medicine for medical institutions, and manufacturing
and quality control standards for cell processing centers. However,
the RMAct also removed a ban on the outsourcing of cell processing
to companies outside medical institutions. Previously, such
outsourcing was considered an infringement of the PMDAct, which
K. Azuma, S. Yamanaka / Regenerative Therapy 4 (2016) 36e47 41prohibits the provision of unapproved products except for those
used in clinical trials.
There are several differences in procedures and requirements
between clinical research under the RM Act and clinical trial under
the PMD Act. Fig. 3 summarizes the differences. As described in the
Section 3.2, PMDA consultations are required before the initiation
of clinical trial under the PMD Act. This process is not trivial, but
provides clarity for regulatory clearance when submitting a clinical
trial plan and new RMP approval application later. On the other
hand, there is no ofﬁcial consultation mechanism before submit-
ting a clinical research plan to the MHLW under the RM Act.
Therefore, the review period of the clinical research plan is longer
in the RM Act (90 days) than is the clinical trial plan in the PMDAct
(30 days). Furthermore, additional data might be requested after
submitting a clinical research plan. The technical requirement of
IRBs (named “specially certiﬁed regenerative medicine commit-
tees” under the RM Act for high risk regenerative therapies such as
iPSC-based therapies) is also stricter in the RM Act than in the PMD
Act.
Clinical research under the RMAct is not subject to Good Clinical
Practice (GCP), which means clinical research data are not accepted
in the new RMP approval application under the PMD Act. However,
in Japan, without ﬁrst-in-human clinical research experience,
companies tend to hesitate to invest money and effort on clinical
trials. Therefore, it is generally considered that clinical research is
more suitable for small-scale clinical study, such as ﬁrst-in-human
study by academia using limited government research funding,
since the costs of clinical research is cheaper than that of clinical
trial. Upon conﬁrmation of feasibility, the technology is transferred
to a company. For example, regarding recently approved “Heart-
Sheet®”, after initial clinical research conducted by a university, a
company conducted additional clinical trials for regulatory sub-
mission according to the PMD Act [84,85].
However, it is also argued that considering the commercializa-
tion of regenerative medicine products in the future, it might be
better to switch from early stage clinical research to clinical trial as
soon as possible or even begin at clinical trial [87]. Since regulatory
requirements for iPSC-based regenerative therapy under the RM
Act are strict, whether the clinical research scheme will be used the
same way as previous guidelines is unclear.
There is another argument that because the RM Act regulates
“clinical practice” outside of “clinical research”, it might be possible
to proceed from clinical research to clinical practices under the RM
Act without commercialization as RMPs. However, this alternative
route may not be suitable for iPSC-based regenerative therapies,
because (1) it is unclear when the iPSC-based regenerative thera-
pies are considered not “clinical research” but rather “clinical
practice”, (2) the RM Act requires a burdensome procedure such as
IRB and MHLW review even for “clinical practice”, and (3) National
Health Insurance coverage scheme for “clinical practice” under the
RM Act is unclear.4. Challenges for international collaboration using clinical
grade iPSCs
In addition to the iPSC stock project at CiRA [51,52], several other
projects, such as those at Cellular Dynamics International Inc. in the
United States (U.S.) and Cell Therapy Catapult in the United
Kingdom, are generating iPSCs prepared from HLA homozygous
donors [121e123]. Other countries are in planning phases for the
same [33]. Assuming these nations meet minimal standards, it is
expected that they can provide iPSCs of a speciﬁc HLA haplotype to
other countries where the same HLA haplotype is relatively rare in
donors [28e34]. Thus, a global cooperation network among theseiPSC banks (haplobanks), or the Global Alliance of iPSC Therapies
(GAiT), has been proposed.
In relation to the commercialization of iPSC therapies, each
country or region has its own regulations and ethical standards.
Although some international guidelines or voluntary standards
for other products can be applied (Fig. 4), because RMPs such as
iPSCs are relatively new, most R&D processes are not in global
agreement. Therefore, to share clinical-grade iPSCs internation-
ally, there are several potential regulatory challenges that must
be overcome. Discussion about these regulatory challenges has
been initiated by several international expert groups such as
International Stem Cell Banking Initiative (ISCBI), International
Alliance for Biological Standardization (IABS) and GAiT
[33,124e126].4.1. Cell sourcing and donor eligibility before iPSC derivation
4.1.1. Informed consent and donor protection
When cells or tissues are sourced from HLA homozygous do-
nors, it is necessary to meet regulation and ethical standards, such
as informed consent, protection of donor privacy, and (non-)
remuneration [127e132]. As recommended for blood donations by
the World Health Organization (WHO) [133], voluntary and non-
remunerated donations of source cells for RMPs are required in
several countries including Japan [130]. As a result, iPSCs derived
from remunerated donors may not be suitable for international
exchange when used as RMPs.
Considering the protection of privacy, how to access potential
donors from cooperating blood centers, cord blood banks or bone
marrow registries are under discussion [29,30,32,126,127,129].
Donor privacy related to genome analysis, including issues around
incidental ﬁndings, are regulated under diverse ethical standards
among countries and also under wider discussion within medical
and ethical communities [9,30,33,127,134e142].4.1.2. Donor screening and testing for infectious agents
The diversity of donor screening regulations might hinder
the acceptance of iPSCs from foreign haplobanks [127,130,131,
143e146]. For example, the Code of Federal Regulations (CFR) of
the U.S. Food and Drug Administration (FDA) requires the use of
“appropriate FDA-licensed, approved, or cleared donor screening
tests” (21 CFR1271.80(c)) and also requires testing be “performed
by a laboratory that either is certiﬁed to perform such testing on
human specimens under the Clinical Laboratory Improvement
Amendments of 1988 (42 U.S.C. 263a) and 42 CFR part 493 or has
met equivalent requirements, as determined by the Centers for
Medicare and Medicaid Services” (21 CFR1271.80(c)) [144]. The
exchange of iPSCs from foreign haplobanks might be hampered by
difﬁculties in conforming speciﬁc requirements across borders,
such as speciﬁcally approved kits and certiﬁed laboratory. A ﬂexible
policy regarding donor screening results under appropriate foreign
regulations is desirable.
The acceptance of iPSCs derived from previously collected cord
blood in foreign countries is also not clear, as cord blood regulations
are not internationally harmonized. For example, in the U.S., cord
blood is subject to biological license approval (BLA) or investiga-
tional new drug (IND) requirements under the Federal Food, Drug,
and Cosmetic Act [123,147], but in Japan cord blood is subject to
different regulations under the Act for Appropriate Provision of
Hematopoietic Stem Cells to be Used in Transplantations
[131,148,149]. Like above, ﬂexible policy for iPSCs derived from cord
blood is desirable.
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(PMD Act) for iPSC-based regenerative therapies. SCRMC, Specially Certiﬁed Regenerative Medicine Committee; IRB, Institutional Review Board.
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cells
4.2.1. Manufacturing methods and raw material information
There are a variety of methods for generating clinical grade
iPSCs using non-integrated vectors such as episomal plasmid,
Sendai virus and mRNA [150e159]. It is expected that several
manufacturing methods will be acceptable from a regulatory
perspective [33]. The use of xeno-free, feeder-free rawmaterials for
manufacturing clinical grade RMPs is generally desirable and
rapidly increasing [154]. It should be carefully checked, however,
whether animal-derived materials are used as or in the
manufacturing process of raw materials and whether the safety of
these materials, such as traceability and virus clearance, if appli-
cable, meet standards. In order to use RMPs based on iPSCs pro-
vided from foreign haplobanks for clinical trials, it is also important
to gain the cooperation of the raw material supplier who provides
necessary information to the manufacturer of the RMPs or to the
foreign regulatory authorities through DMF registration, as
described in the Section 3.3, or similar mechanisms.
4.2.2. Quality standards
Quality standards for iPSCs of research-grade and clinical-grade
have been already discussed in several academic societies or con-
sortiums, such as the International Stem Cell Banking Initiative
[33,124,155,157,160,161]. Other existing guidelines for biotech-
nology products, such as those of the International Conference on
Harmonisation1 of Technical Requirements for Registration of1 Renamed to the International Council for Harmonisation on October 2015
(http://www.ich.org/about/organisational-changes.html).Pharmaceuticals for Human Use (ICH) might be applicable for the
generation of a master cell bank [162,163]. Clear regulatory guide-
lines for the evaluation of iPSCs and RMPs may be helpful to pro-
mote efﬁcient R&D. However, to further reﬁne the standards
necessary for iPSCs, it might be necessary to gather more data of
both iPSCs and iPSC-based RMPs under a collaborative mechanism
between haplobanks and user research centers developing RMPs,
as exempliﬁed in the Section 2.2. For the time being, it is expected
that so long ﬁnal products are safe and effective, they will receive
approval by regulatory authorities that consider appropriate spec-
iﬁcation of iPSCs as a raw material and ﬁnal product, even without
international consensus on standards or regulatory guidelines.
Because different clones of iPSCs from the same donor may have
different propensities of differentiation [164], it is probably best to
defer to user research centers for the selection of clones until better
predictive methods for differentiation propensity are established
[165]. In addition, because iPSC-based RMPs vary in characteristics
and number of cells, quality standards for one product may not be
universal. For example, there is less need to concern platelets
derived from iPSCs [166] with tumorigenicity resulting from
genomic abnormalities compared with other RMPs, because of the
absence of a genome in platelets. Therefore, universal standards
risk inefﬁciencies. Another issue relates to the donor background.
Depending on the disease targeted by the RMP, additional re-
quirements of the donor's health and genetic background or spe-
ciﬁc virus screening might be necessary [167]. For example,
allogeneic clinical trials of retinal pigment epithelium cells need
screenings for retinal diseases [77,168]. Considering the above is-
sues, it will be desirable to have regulator-led international forums,
such as ICH, include academic experts in order to develop ﬂexible
but sufﬁcient criteria for multi-purpose iPSC haplobanks that
leverage empirical evidence generated from scientiﬁc studies.
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GMP for RMPs or GCTP in many countries is generally consis-
tent with the Pharmaceutical Inspection Convention and Phar-
maceutical Inspection Co-operation Scheme (jointly referred to as
PIC/S) GMP Guide, which was drafted in consultation with phar-
maceutical inspection authorities from 46 countries [169e171].
However, it is not yet clear to what extent GMP controls are
required for the generation of iPSCs, which are at a relatively early
stage of the manufacturing process and well before the stage of a
master cell bank for speciﬁc RMPs [32,143,172]. In addition global
cooperation for haplobanks may require each haplobank receives
inspection from several national regulatory authorities. A higher
level of regulatory cooperation in order to mutually rely on the
GMP inspection reports from other regulatory authorities is
desirable [173].
4.2.4. Addition of iPSCs to existing RMPs
Another unresolved issue unique to iPSC-based RMPs, especially
regarding haplobanks, is the extent of additional tests for the in-
clusion of new iPSC lines [33,143]. The same product from different
cell lines may not have universal properties. Therefore, a number of
causes for the variability must be considered, including(1) changes from clones of the same donor,
(2) different donors from the same manufacturing site and
manufacturing method,
(3) changes in manufacturing methods (including changes in
media or reagents) from the same manufacturing site,
(4) different manufacturing sites from the same manufacturing
method, and
(5) different manufacturing methods that meet the same spec-
iﬁcations and criteria.
Changes in cell lines and master cell banks are allowed in pre-
viously approved allogeneic RMPs, such as Apligraf®, or Gintuit™,
both from Organogenesis Inc, in the U.S. based on extensive char-
acterization and through premarket approval supplement for
manufacture process change [172,174]. A similar approach for new
iPSC lines would allow approval holders of RMPs derived fromHLA-
homozygous iPSCs to add new HLA-type iPSC lines to existing
RMPs. However, there is neither agreement for required compara-
bility data nor scientiﬁc evidence to justify that changes in the cell
bank do not affect product safety or efﬁcacy. If the new iPSC line
requires excessive testing, cost may prohibit the inclusion of this
line for RMP development, potentially resulting in the RMP only
K. Azuma, S. Yamanaka / Regenerative Therapy 4 (2016) 36e4744serving patients with frequent HLA phenotypes, thus creating an
ethical conﬂict. Regulatory judgment that considers maximization
of public health in accordance with the concept of regulatory sci-
ence should be applied [175].5. Conclusion
In this article, we reviewed recent developments of collabora-
tive R&D schemes between clinical grade iPSC manufacturers and
user research centers, as well as government policies to facilitate
the establishment of R&D and regulatory infrastructures in Japan.
In addition, we reviewed potential challenges for further collabo-
ration with research center overseas. We expect some of these
challenges will be resolved with growing scientiﬁc knowledge
gained from pre-clinical studies and the clinical development of
RMPs. The resolution of other issues for the wide deployment of
iPSC therapies should come from further collaboration between
regulators and researchers.Conﬂict of interest
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